Clinical trial
Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That…
NCT00470470 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00470470 |
|---|---|
| Title | Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery |
| Official title | A Phase II Study of Imatinib Mesylate (STI571;NSC#716051:IND 61135) in Patients With Inoperable AJCC Stage III or IV Melanoma Harboring Somatic Alterations of C-KIT |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Acral Lentiginous Malignant Melanoma, Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma |
| Intervention type | Drug, Other |
| Interventions | imatinib mesylate, laboratory biomarker analysis |
| Enrollment | 30 |
| Start date | Apr 1, 2007 |
| Primary completion | Dec 1, 2013 |
| Completion | Oct 1, 2014 |
| First posted | May 7, 2007 |
| Last update posted | Dec 23, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: